Diagnosis and management of inflammatory bowel disease in children

Seminars in Pediatric Surgery

Volumn 16, Issue 3, 2007, Pages 164-171

  Carvalho, Ryan ^a   Hyams, Jeffrey S ^b,c  

^a WRIGHT STATE UNIVERSITY   (United States)

^b Division of Pediatric Infectious Diseases   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Biologic therapy; Corticosteroids; Crohn's disease; Immunomodulators; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MLN 02; NATALIZUMAB; PLACEBO; SALAZOSULFAPYRIDINE; TIOGUANINE; VISILIZUMAB;

ADOLESCENT DISEASE; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CAPSULE ENDOSCOPY; CHILDHOOD DISEASE; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DRUG DEPENDENCE; DYSPNEA; ENTERITIS; FEVER; FLUSHING; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPOTENSION; INFECTION; INFECTIOUS COMPLICATION; INTESTINE ENDOSCOPY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MYALGIA; MYCOSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PRURITUS; RADIODIAGNOSIS; RASH; SERODIAGNOSIS; SIDE EFFECT; T CELL LYMPHOMA; THORAX PAIN; ULCERATIVE COLITIS; UNITED STATES; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL MARKERS; CAPSULE ENDOSCOPY; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; DIAGNOSTIC IMAGING; ENDOSCOPY, GASTROINTESTINAL; HUMANS; TREATMENT OUTCOME;

EID: 34250877764     PISSN: 10558586     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2007.04.003     Document Type: Article

References (72)

1. Kugathasan S., Judd R.H., Hoffmann R.G., et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 143 (2003) 525-531
2. Bernstein C.N., Wajda A., Svenson L.W., et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 101 (2006) 1559-1568
3. Cuffari C. Inflammatory bowel disease in children: a pediatrician's perspective. Minerva Pediatr 58 (2006) 139-157
4. Beattie R.M., Walker-Smith J.A., and Murch S.H. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 73 (1995) 354-355
5. Langhorst J., Elsenbruch S., Mueller T., et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 11 (2005) 1085-1091
6. Bunn S.K., Bisset W.M., Main M.J., et al. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 32 (2001) 171-177
7. Sharif F., McDermott M., Dillon M., et al. Focally enhanced gastritis in children with Crohn's disease and ulcerative colitis. Am J Gastroenterol 97 (2002) 1415-1420
8. Zholudev A., Zurakowski D., Young W., et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 99 (2004) 2235-2241
9. Mow W.S., Vasiliauskas E.A., Lin Y.C., et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126 (2004) 414-424
10. Desir B., Amre D.K., Lu S.E., et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol 2 (2004) 139-146
11. Dubinsky M.C., Lin Y.C., Dutridge D., et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 101 (2006) 360-367
12. Dubinsky M.C., Ofman J.J., Urman M., et al. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 96 (2001) 758-765
13. Amre D.K., Lu S.E., Costea F., et al. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol 101 (2006) 645-652
14. Hui T., Landers C., Vasiliauskas E., et al. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis Colon Rectum 48 (2005) 1254-1262
15. Kornbluth A., Legnani P., and Lewis B.S. Video capsule endoscopy in inflammatory bowel disease: past, present, and future. Inflamm Bowel Dis 10 (2004) 278-285
16. Chong A.K., Taylor A., Miller A., et al. Capsule endoscopy vs. push enteroscopy and enteroclysis in suspected small-bowel Crohn's disease. Gastrointest Endosc 61 (2005) 255-261
17. Triester S.L., Leighton J.A., Leontiadis G.I., et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease. Am J Gastroenterol 101 (2006) 954-964
18. Rondonotti E., Herrerias J.M., Pennazio M., et al. Complications, limitations, and failures of capsule endoscopy: a review of 733 cases. Gastrointest Endosc 62 (2005) 712-716
19. Pallotta N., Tomei E., Viscido A., et al. Small intestine contrast ultrasonography: an alternative to radiology in the assessment of small bowel disease. Inflamm Bowel Dis 11 (2005) 146-153
20. Calabrese E., La Seta F., Buccellato A., et al. Crohn's disease: a comparative prospective study of transabdominal ultrasonography, small intestine contrast ultrasonography, and small bowel enema. Inflamm Bowel Dis 11 (2005) 139-145
21. Darbari A., Sena L., Argani P., et al. Gadolinium-enhanced magnetic resonance imaging: a useful radiological tool in diagnosing pediatric IBD. Inflamm Bowel Dis 10 (2004) 67-72
22. Godefroy C., Pilleul F., Dugougeat F., et al. [Value of contrast-enhanced MR enterography in pediatric Crohn's disease: preliminary study]. J Radiol 86 (2005) 1685-1692
23. Bodily K.D., Fletcher J.G., Solem C.A., et al. Crohn Disease: mural attenuation and thickness at contrast-enhanced CT enterography: correlation with endoscopic and histologic findings of inflammation. Radiology 238 (2006) 505-516
24. Hanauer S.B. Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther 20 suppl 4 (2004) 97-101
25. Summers R.W., Switz D.M., Sessions Jr. J.T., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77 (1979) 847-869
26. Singleton J.W., Hanauer S.B., Gitnick G.L., et al., Pentasa Crohn's Disease Study Group. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 104 (1993) 1293-1301
27. Hanauer S.B., and Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2 (2004) 379-388
28. Camma C., Giunta M., Rosselli M., et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 113 (1997) 1465-1473
29. Ardizzone S., Maconi G., Sampietro G.M., et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127 (2004) 730-740
30. Hyams J., Markowitz J., Lerer T., et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 4 (2006) 1118-1123
31. Markowitz J., Hyams J., Mack D., et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 4 (2006) 1124-1129
32. Thomsen O.O., Cortot A., Jewell D., et al., International Budesonide-Mesalamine Study Group. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med 339 (1998) 370-374
33. Sandborn W.J., Lofberg R., Feagan B.G., et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 100 (2005) 1780-1787
34. Kundhal P., Zachos M., Holmes J.L., et al. Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr 33 (2001) 75-80
35. Dilger K., Alberer M., Busch A., et al. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. Aliment Pharmacol Ther 23 (2006) 387-396
36. Hawthorne A.B., Logan R.F., Hawkey C.J., et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 305 (1992) 20-22
37. Verhave M., Winter H.S., and Grand R.J. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 117 (1990) 809-814
38. Ramakrishna J., Langhans N., Calenda K., et al. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 22 (1996) 296-302
39. Markowitz J., Grancher K., Kohn N., et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119 (2000) 895-902
40. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 (2005) 1121-1125
41. Feagan B.G., Rochon J., Fedorak R.N., et al., The North American Crohn's Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N Engl J Med 332 (1995) 292-297
42. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
43. Mamula P., Markowitz J.E., Cohen L.J., et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 38 (2004) 298-301
44. Jarnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
45. Treem W.R., Cohen J., Davis P.M., et al. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum 38 (1995) 474-479
46. Feagan B.G., Greenberg G.R., Wild G., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 352 (2005) 2499-2507
47. Mori K., Yoshihara T., Ando T., et al. Cytapheresis therapy for ulcerative colitis in three pediatric patients. J Pediatr Gastroenterol Nutr 39 (2004) 549-551
48. Naganuma M., Funakoshi S., Sakuraba A., et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 10 (2004) 251-257
49. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
50. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
51. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
52. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
53. Hyams J., Crandall W., Kugathasan S., et al. Induction and maintenance therapy with infliximab for the treatment of modere to severe Crohn's disease in children. Gastroenterology 132 (2007) 863-873
54. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2 (2004) 542-553
55. Brooklyn T.N., Dunnill M.G., Shetty A., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55 (2006) 505-509
56. Rutgeerts P., Van Assche G., and Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126 (2004) 1593-1610
57. Vermeire S., Noman M., Van Assche G., et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125 (2003) 32-39
58. Lichtenstein G.R., Sbreu M.T., Cohen R., et al. [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease]. Rev Gastroenterol Mex 71 (2006) 351-401
59. Thayu M., Markowitz J.E., Mamula P., et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 40 (2005) 220-222
60. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006) 323-333
61. Schreiber S., Rutgeerts P., Fedorak R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 (2005) 807-818
62. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 (2005) 1912-1925
63. Hyams J.S., Wilson D.C., Thomas A., et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr 44 (2007) 185-191
64. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933
65. Kugathasan S., Dubinsky M.C., Keljo D., et al. Severe colitis in children. J Pediatr Gastroenterol Nutr 41 (2005) 375-385
66. Griffiths A.M., Ohlsson A., Sherman P.M., et al. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 108 (1995) 1056-1067
67. DiFedele L.M., He J., Bonkowski E.L., et al. Tumor necrosis factor alpha blockade restores growth hormone signaling in murine colitis. Gastroenterology 128 (2005) 1278-1291
68. Ballinger A.B., Camacho-Hubner C., and Croft N.M. Growth failure and intestinal inflammation. QJM 94 (2001) 121-125
69. Hyams J.S., Moore R.E., Leichtner A.M., et al. Relationship of type I procollagen to corticosteroid therapy in children with inflammatory bowel disease. J Pediatr 112 (1988) 893-898
70. Brandt L.J., Bernstein L.H., Boley S.J., et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 83 (1982) 383-387
71. Rutgeerts P., Hiele M., Geboes K., et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 108 (1995) 1617-1621
72. Gionchetti P., Rizzello F., Lammers K.M., et al. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol 12 (2006) 3306-3313